Form 4: Astrana Health Director Exercises Options, Sells Shares

Astrana Health Director Mitchell W. Kitayama exercised stock options and subsequently sold a portion of his common stock back to the issuer.

Summary

• Director Mitchell W. Kitayama engaged in transactions involving Astrana Health, Inc. common stock and stock options on September 15, 2025.
• Exercised 8,000 stock options at an exercise price of $18.2 per share, which were fully vested and exercisable.
• Disposed of 8,000 common shares at $30.23 per share, which were repurchased by the Issuer.
• Disposed of an additional 5,214 common shares at $30.23 per share, also repurchased by the Issuer.
• Following these transactions, beneficial ownership includes 15,846 common shares, of which 6,449 are restricted shares vesting on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• Retains beneficial ownership of 12,000 stock options with an expiration date of November 11, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual report of insider transactions, which includes both the exercise of options (often seen as positive) and the sale of shares (neutral to slightly negative, depending on context, but here it's an issuer repurchase). The overall sentiment is neutral as it's a routine disclosure without explicit forward-looking statements or significant strategic implications.

Positives

• Director exercised 8,000 fully vested stock options at $18.2 per share, indicating a realization of value from previously granted equity.

Negatives

• Director disposed of a total of 13,214 common shares (8,000 and 5,214 shares) through repurchases by the Issuer at $30.23 per share, reducing direct common stock holdings.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The Issuer repurchased 13,214 common shares from Director Mitchell W. Kitayama, representing a transaction between a related party (director) and the company.

Stakeholder Impact

• Shareholders may observe the director's decision to exercise options and sell shares, which could provide insight into insider activity and sentiment regarding the stock.

Next Steps

• Vesting of 6,449 restricted shares on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• Expiration of 12,000 stock options on November 11, 2025.

Key Dates

Keywords

Astrana Health, ASTH, Form 4, Insider Transaction, Stock Options, Share Repurchase, Director, Equity Compensation